{
    "eid": "2-s2.0-85164270417",
    "title": "Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "COVID-19 vaccines",
        "heterologous booster",
        "inactivated",
        "NVX-CoV2373",
        "protein-based",
        "viral vector"
    ],
    "authors": [
        "Anthony M. Marchese",
        "Raj Kalkeri",
        "Muruga Vadivale",
        "Nungruthai Suntronwong",
        "Seth Toback",
        "Yong Poovorawan"
    ],
    "citedby-count": 0,
    "ref-count": 63,
    "ref-list": [
        "Inactivated viral vaccines",
        "Mechanisms of action of adjuvants",
        "Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial",
        "Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial",
        "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",
        "Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico",
        "Efficacy and safety of the RBD-Dimer-based Covid-19 vaccine ZF2001 in adults",
        "NVX-Cov2373 vaccine efficacy against hospitalization: a post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial",
        "An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled study",
        "Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial",
        "Safety and efficacy of single-dose ad26.COV2.S vaccine against covid-19",
        "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",
        "Understanding modern-day vaccines: what you need to know",
        "Adenovirus vectors: excellent tools for vaccine development",
        "The current status of adenovirus-based cancer gene therapy",
        "Adenoviral vectors for gene therapy",
        "Current advances and future challenges in Adenoviral vector biology and targeting",
        "Adenovirus: from foe to friend",
        "Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCoV-19) Covid-19 vaccine",
        "Vaccine adjuvants: from 1920 to 2015 and beyond",
        "With established safe and effective use, protein vaccines offer another choice against COVID-19",
        "The matrix-M adjuvant: a critical component of vaccines for the 21(st) century",
        "Safety and Efficacy of NVX-CoV2373 Covid-19 vaccine",
        "Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials",
        "Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial",
        "Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis",
        "Omicron thwarts some of the world\u2019s most-used COVID vaccines",
        "Tracking Coronavirus Vaccinations Around the World",
        "Safety and Immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine: an interim analysis",
        "A randomized, controlled study to evaluate the safety and immunogenicity of a heterologous booster dose of an adjuvanted SARS CoV-2 recombinant spike protein vaccine in adults",
        "Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(tm)) after homologous and heterologous two-dose regimens",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",
        "Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial",
        "Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination",
        "Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial",
        "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine",
        "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine",
        "Mix-and-match COVID-19 vaccinations (heterologous boost): a review",
        "Homologous and heterologous Covid-19 booster vaccinations",
        "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
        "Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination",
        "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial",
        "Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination",
        "Durability of Heterologous and homologous COVID-19 vaccine boosts",
        "Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of coronavac vaccination",
        "Vaccines and Related Biological Products Advisory Committee (VRBPAC)",
        "Immunogenicity and safety of NVX-CoV2373 as a homologous or heterologous booster: a phase 3 randomized clinical trial in adults",
        "COVID-19 vaccine makers plan for annual boosters, but it\u2019s not clear they\u2019ll be needed",
        "Global state of education-related inequality in COVID-19 vaccine coverage, structural barriers, vaccine hesitancy, and vaccine refusal: findings from the Global COVID-19 Trends and Impact Survey",
        "Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination",
        "Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Gaithersburg",
            "@id": "60138508",
            "affilname": "Novavax, Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138508",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Novavax, Inc."
    ]
}